LC–MS/MS method for the quantitation of OCT1 biomarker isobutyrylcarnitine in human plasma with clinical sample analysis: supplementary data

Aim: Isobutyrylcarnitine (IBC) is a possible biomarker for hepatic OCT1, as IBC plasma concentrations are
reduced when OCT1 is inhibited. An accessible, characterized assay is needed to quantitate IBC in human
plasma. Materials & methods: A triple quadrupole MS surrogate matrix assay for the quantitation of
IBC was characterized to support a first-in-human study. Results: An assay for IBC quantitation was fully
characterized for accuracy, precision, selectivity and parallelism. IBC was measured in a clinical study and
the data were correlated to the in vitro model prediction. Conclusion: A triple quadrupole-based assay
for IBC should broaden the monitoring of IBC for OCT1 inhibition in early clinical trials, generating the
data needed to establish IBC as a valid biomarker.